Market Overview

GW Pharmaceutical's Upcoming Epidiolex Data Has Relatively Low Bar for Success

Share:
Related GWPH
GW Pharmaceuticals Gets Orphan Drug Status For Cannabidiol, Stock Rises
Why You Should Be Excited About GW Pharma
GW Pharmaceuticals: A Cannabis Stock That's Way Too High To Make Any Sense (Seeking Alpha)

On Tuesday, Leerink reiterated an Outperform rating on GW Pharmaceuticals (NASDAQ: GWPH) and $79 price target.

Analyst Joseph Schwartz believes the “bar for success is relatively low” for upcoming Epidiolex data, based on the review of epilepsy trials. Schwartz went on to explain that 20 to 50 percent reduction in seizures versus placebo is generally good enough to approve add-on treatments.

In the second half of 2014, the company will start placebo-controlled proof-of-concept study followed by studies in Dravet and Lennox-Gastaut syndrome in 2015.

Shares closed up 1.5 percent to $66.19 in Tuesday's trading.

Latest Ratings for GWPH

DateFirmActionFromTo
Mar 2016Roth CapitalMaintainsBuy
Mar 2016Numis SecuritiesInitiates Coverage onSell
Nov 2015Roth CapitalAssumesBuy

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Joseph Schwartz LeerinkAnalyst Color Reiteration Analyst Ratings

 

Related Articles (GWPH)

View Comments and Join the Discussion!